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Abstract
Background: The systemic injection of neural stem/precursor cells (NPCs) provides remarkable amelioration of the clinico-
pathological features of experimental autoimmune encephalomyelitis (EAE). This is dependent on the capacity of
transplanted NPCs to engage concurrent mechanisms of action within specific microenvironments in vivo. Among a wide
range of therapeutic actions alternative to cell replacement, neuroprotective and immune modulatory capacities of
transplanted NPCs have been described. However, lacking is a detailed understanding of the mechanisms by which NPCs
exert their therapeutic plasticity. This study was designed to identify the first candidate that exemplifies and sustains the
immune modulatory capacity of transplanted NPCs.
Methodology/Principal Findings: To achieve the exclusive targeting of the peripheral immune system, SJL mice with PLP-
induced EAE were injected subcutaneously with NPCs and the treatment commenced prior to disease onset. NPC-injected
EAE mice showed significant clinical improvement, as compared to controls. Exogenous NPCs lacking the expression of
major neural antigens were reliably (and for long-term) found at the level of draining lymph nodes, while establishing
sophisticated anatomical interactions with lymph node cells. Importantly, injected NPCs were never found in organs other
than lymph nodes, including the brain and the spinal cord. Draining lymph nodes from transplanted mice showed focal up-
regulation of major developmental stem cell regulators, such as BMP-4, Noggin and Sonic hedgehog. In lymph nodes,
injected NPCs hampered the activation of myeloid dendritic cells (DCs) and steadily restrained the expansion of antigen-
specific encephalitogenic T cells. Both ex vivo and in vitro experiments identified a novel highly NPC-specific–BMP-4-
dependent–mechanism hindering the DC maturation.
Conclusion/Significance: The study described herein, identifies the first member of the TGF b/BMP family of stem cell
regulators as a novel tolerogenic factor released by NPCs. Full exploitation of this pathway as an efficient tool for
vaccination therapy in autoimmune inflammatory conditions is underway.
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Introduction
Spontaneous neural tissue repair may occur in acute and/or
chronic inflammatory and degenerative disorders of the nervous
system such as multiple sclerosis (MS). However, this process is not
robust to promote a full functional and stable recovery of the
nervous system architecture [1]. Recent advances in (stem) cell
biology have raised great expectations that diseases and injuries of
the central nervous system (CNS) may be ameliorated by the
development and delivery of cell therapies. Though, most (if not
all) of the experimental cell therapies described, injecting neural
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tissue repair in disease models where the anatomical and
functional damage is widespread and an inflamed and/or
degenerative microenvironment co-exists [2]. In contrast, the
systemic injection of somatic, and more recently embryonic stem
(ES) cell-derived, neural stem/precursor cells (NPCs) has provided
remarkable amelioration of the clinico-pathological features of
rodents with acute, chronic and relapsing experimental autoim-
mune encephalomyelitis (EAE), the animal model of MS [3,4,5,6].
This phenomenon has been shown to be dependent on the
capacity of transplanted NPCs to engage multiple mechanisms of
action within specific microenvironments in vivo [7]. Among a wide
range of potential therapeutic actions, and, in addition to the
(expected) cell replacement [3], remarkable neuroprotective and
immunemodulatorycapacitieshavebeendescribedfortransplanted
NPCs within specific CNS [3,4,5,6] as compared to non-CNS areas
[8]. As such, we and others have provided considerable proof that
NPC-mediatedbystandereffects maytake placeboth intheCNS,at
the level of the atypical perivascular niches [6], as well as in
secondary lymphoid organs, such as the lymph nodes [8] or the
spleen [9]. Nonetheless, following the first report that membrane-
bound Fas/CD90 ligands (e.g., Apo3L, TRAIL and FasL) were
regulating part of the NPC-mediated suppressive effect on
encephalitogenic T lymphocytes in the CNS [6], other groups have
generated data albeit indirectly that describe the mechanisms
responsible for this peculiar somatic stem cell function. In general,
this has been supported in studies that utilized in vitro immune cell/
NPC co-cultures [4,5,10], although these studies have provided
evidence describing only the short-term in vivo persistence of
transplanted NPCs into peripheral (non-CNS) bodily organs [8,9].
Concurrently, recent reports have begun to elucidate paracrine
factors that are responsible for mediating the immune suppressive vs
pro-survival capacity of other somatic stem cell sources; these
includechemokinesandinduciblenitricoxide(iNOS)[11]andmore
recentlystanniocalcin-1(STC-1),apeptidehormonethatmodulates
mineral metabolism [12]. Importantly though, the detailed
molecular and cellular mechanism(s) responsible for sustaining the
multifacetedtherapeuticplasticityexhibitedbyNPCsinvivoremain
far from being fully elucidated, characterized and described.
Herein we report the capacity of NPCs to target, and synergize
withimmunecellsinsecondarylymphoidorgans(e.g.,draninglymph
nodes), and have demonstrated this by utilizing a highly peculiar
protocol of therapeutic passive NPC vaccination in mice affected by
experimental chronic-recurrent autoimmune CNS inflammation.
Subcutaneously (s.c.)-injected NPCs accumulate and survive over
twomonthswithindraininglymphnodes,butnotintheCNS,where
they stably modify the perivascular lymph node microenvironment.
Within this context, surviving NPCs hamper the activation of
myeloid dendritic cells (DC) via the release of major developmental
stem cell regulators, includingthe morphogens bone morphogenetic
protein (BMP)-4 and sonic hedgehog (Shh), the extracellular matrix
protein tenascin C, and the BMP antagonist Noggin.
Nonetheless, we identify a novel BMP-4-dependent mechanism
hindering the DC maturation, both in vivo and in vitro. This
BMP-dependent effect is highly specific for immune regulatory
NPCs, and, in turn, lead to the steady restraint of the expansion of
antigen-specific (encephalitogenic) T cells.
Results
Protection of EAE mice upon accumulation of s.c.-
injected NPCs into draining lymph nodes
SJL mice suffering from relapsing-remitting experimental
autoimmune encephalomyelitis (R-EAE), a model of chronic-
relapsing autoimmune CNS inflammation leading to demyelin-
ation and axonal loss [6], were injected s.c. into the flanks with
subventricular zone (SVZ)-derived syngenic adult NPCs (1.0610
6
cells per mouse). Green fluorescent protein (GFP)
+ NPCs were
injected at either 3 and 10 days post immunization (dpi) with the
myelin autoantigen proteolipid protein (PLP)139–151, or at 10 dpi
only. Regardless of the timing or number of injections, both
groups of NPC-injected R-EAE mice showed significant clinical
improvement, as compared to sham-treated controls. Further,
mice injected at 10 dpi only, showed a significant delay of disease
onset (p#0.005, vs. sham-treated controls). At the end of the
follow up period (75 dpi), both groups of NPC-treated mice
showed significantly lower R-EAE cumulative score, fewer clinical
relapses, and lower burden of spinal cord inflammation (from 46 to
64% reduction), demyelination (from 84 to 98% reduction) and
axonal damage (from 89 to 93% reduction), as compared to sham-
treated controls. Finally, delayed injection (injected at 30 dpi) of live
NPCs or paraformaldehyde (PFA)-fixed NPCs (injected at 10 dpi)
did not produce any detectable clinical improvement, as compared
to sham-treated controls (Figure S1). The clinico-pathological
features of R-EAE mice injected s.c. with different NPC types are
summarised in Table 1 and Figure S1.
To assess quantity, morphology and distribution of s.c.-injected
NPCs, a detailed histological analysis was performed at 75 dpi in
both the CNS (e.g., brain and spinal cord) and peripheral tissues
such as spleen, liver, kidneys and draining lymph nodes from
transplanted R-EAE mice. Quite distinct from what occurs upon
injection of NPCs either intravenously or intrathecally into EAE
rodents after disease onset [3,6,13], we did not find s.c.-injected
Table 1. Clinico-pathological features of R-EAE mice injected s.c. with NPCs.
Treatment
Treatment
schedule
No. of
mice
Disease
onset
(dpi)
{
Maximum
clinical
score
{
Cumulative
disease
score
{{
Number of
relapses
Inflammatory
infiltrates
1*
(no./mm
2)
Demyelination
1{
(%/mm
2)
Axonal loss
1{
(%/mm
2)
Sham 3 and 10 dpi 10 15.860.9 2.3560.07 110.3567.7 2.1460.1 3.360.6 1.1760.3 0.9560.2
NPCs 3 and 10 dpi 15 15.661 1.7560.2
* 83612.7
* 1.560.2
* 1.260.3
** 0.1960.09
** 0.160.04
**
NPCs 10 dpi 15 21.261.5
** 1.8760.1
* 69.969.5
** 1.260.1
** 1.860.4
* 0.0260.01
** 0.0760.02
**
{Data are mean numbers (6SEM) from a total of n=2 independent experiments. dpi, days post-immunization.
{The cumulative score represents the summation of each single score recorded for each mouse from the day of immunization (day 0) to day of sacrifice (75 dpi).
1Inflammatory infiltrates, demyelination and axonal loss have been quantified at sacrifice (75 dpi) on an average of n$20 spinal cord sections per mouse from a total of
n=3 mice per group.
*p#0.05 when compared with sham-treated controls.
**p#0.005 when compared with sham-treated controls.
doi:10.1371/journal.pone.0005959.t001
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+ cells in the brain, spinal cord, liver, spleen and kidneys. On
the other hand, GFP
+ NPCs were consistently found at both early
(e.g., 2 weeks after cell injection) as well as late (e.g., 65–72 days
after cell injection) time points in the draining lymph nodes of all
NPC-injected R-EAE mice (following both treatment schedules).
The number of GFP
+ cells accumulating and persisting for at 65–
72 days after cell injection within draining lymph nodes varied
only moderately from case to case. The highest number of GFP
+
NPCs was observed in axillary and cervical lymph nodes proximal
to the cell injection site(s). While the lymph node architecture was
preserved and low-power examination did not disclose any
alteration, NPCs predominantly accumulated as focal clusters
around blood vessels of the hilum and medullary/paracortical
areas (Figure 1A). The great majority of s.c.-injected NPCs
survived long term (greater than 2 months after transplantation)
within lymph nodes, while lacking the expression of major antigens
of the neural lineage, such as polysialylated neural cell adhesion
molecule (PSA-NCAM), class III b–Tubulin, neuronal nucleus
Figure 1. S.c.-injected NPCs accumulate and persist in secondary lymphoid organs from R-EAE mice while lacking the expression of
major antigens of the neural lineage. A, Sagittal reconstruction of a representative axillary lymph node from a R-EAE mouse injected s.c. with
syngeneic NPCs. GFP
+ NPCs (green) are detected throughout the entire lymph node tissue although they predominantly accumulate as focal clusters
in the hilum (Hi), medulla (Me), and paracortex (Pcx). Some of the NPCs are in close contact with CD11b
+ macrophages (red). Twenty % of NPCs
express the early neuronal differentiation marker doublecortin (DCX) (blue). Scale bar: 300 mm. B–D, Occasionally, GFP
+ NPCs (B) expressing the neural
cell marker nestin (C) are detected in perivascular lymph node areas. The panel in D is a merged image of the pictures in B and C; E, Representative
image of a cervical lymph node where NPCs (green, arrowhead) are found to establish close anatomical interaction(s) with von Willebrand factor
antigen-expressing endothelial cells (red); F, Confocal microscopy image of a para-aortic lymph node where NPCs (green, arrowheads) are found in
close cell-to-cell contact with CD11c
+ DCs (red). G and H, Axillary lymph node sections showing persistence of NPCs (green, arrowheads) in areas
colonized by F4/80
+ phagocytes (G, red) and MHC class-II
+ immune cells (H, red). Occasionally, F4/80
+ cells being immunoreactive also for GFP (G,
dashed arrow in the boxed area) are identified. NPCs are in green in A–H. Nuclei in B, D and E–H are counterstained with DAPI. Scale bars in B–H:
40 mm. Data refer to R-EAE mice injected s.c. with NPCs at 3 and 10 dpi and sacrificed 72 days after cell injection.
doi:10.1371/journal.pone.0005959.g001
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derived growth factors receptor (PDGFr)a. However, 20% of the
GFP
+ NPCs expressed the early neuronal differentiation marker
doublecortin (DCX) (Figure 1A and Figure S2), while10% of GFP
+
NPCs were immune reactive for the neural cell marker nestin in
lymph nodes (Figure 1B–D).
Interaction(s) of NPCs and lymph node cells at the level
of perivascular areas
In lymph nodes, NPCs established anatomical interaction(s)
with von Willebrand factor-immunoreactive endothelial cells
(Figure 1E) and were identified in close cell-to-cell contact with
lymph node cells (LNCs), such as CD11c
+ dendritic cells (DCs)
(Figure 1F), F4/80
+ professional phagocytes (Figure 1G) and major
histocompatibility complex (MHC) class II
+ immune cells
(Figure 1H). While GFP
+ NPCs and neighbouring LNCs
maintained mutually exclusive fluorescence patterns (Figure 1F
and H), only very few phagocytes (5–10% of the total GFP
+ cells in
lymph nodes) were double positive for the GFP and the phagocyte
markers F4/80 or CD11b. This suggested that a very low number
of s.c.-injected NPCs might have undergone phagocytosis
(Figure 1G and Figure S2).
The ultrastructural analysis of lymph nodes from NPC-injected
R-EAE mice confirmed the presence of numerous large-size GFP
+
cells with electrodense grain precipitates displaying morphological
and ultrastructural features similar to neurospheres in vitro
(Figure 2 and Figure S3). These GFP
+ cell were rich in organelles,
displayed an endoplasmic reticulum with short cisterns and
invaginated nucleus with clumped chromatin and were frequently
found in close contact with LNCs (Figure 2A). Individual GFP
+
NPCs were found to establish consistent anatomical contacts with
LNCs through either polarized microvilli (nanotubes) (Figure 2B),
cytoplasmic expansions (Figure 2C) or elongated intercellular
junctions (Figure 2D). Transplanted NPCs were also occasionally
found in deeper contact and enclosing resident lymph cells, up to
membrane fusion (Figure 2E), and infrequently, GFP
+ NPCs
showed cytoplasmic vacuoles and picnotic nuclei (Figure S2).
Establishment of ectopic germinal niche-like areas in
lymph nodes
We then sought to investigate the molecular features of the
lymph node areas appearing as preferential sites of accumulation
and, importantly, long term persistence of s.c.-injected NPCs.
Interestingly, lymph nodes from R-EAE mice showed focal high
(re)expression of extracellular matrix proteins typical of germinal
CNS niches, such as tenascin C [14], as well as major stem cell
regulators, such as BMP-4 and -7 (but not BMP-2) [15,16], and
Shh [17,18] (Figure 3A–D), when compared to lymph nodes from
control non-EAE mice. Among these regulators, only BMP-4
(Figure 3E), the BMP antagonist Noggin (Figure 3F), and Shh
(Figure 3G) were significantly increased (by 3 to 4-fold) in the
axilliary lymph nodes from mice s.c.-injected with NPCs, as
compared to sham-treated controls.
We then hypothesised that the establishment of a permissive
ectopic germinal niche-like micro-environment in perivascular lymph
node areas–molecularly reminiscent of that described in the adult
brain upon NPC transplantation [6,19,20] –might have allowed
the survival, and possibly sustained the function, of s.c.-injected
NPCs.
Inhibition of the generation of encephalitogenic T cells
We next investigated whether the observed close vicinity (and
interaction) between s.c.-injected NPCs and LNCs within favour-
able lymph node microenvironments might have had major
immunological effects, such as the impairment of the generation of
effector (CD4
+) T cells responsible for the chronic CNS-confined
inflammation observed in EAE [21].
We first found that lymph node T cells from NPC-transplanted
R-EAE mice displayed a significantly lower proliferation rate ex
vivo in response to PLP139–151, as compared to T cells from
sham-treated R-EAE control mice. The same magnitude of
unresponsiveness was observed in cervical, axillary and inguinal
lymph nodes (p#0.05) (Figure 4A). Consistently, LNCs isolated
from SJL mice 10 days after PLP139–151 immunization and co-
cultured in vitro with NPCs (LNCs/NPCs) showed: (i) a significant
impairment of PLP139–151-specific T cell proliferation [p#0.05,
vs. (non co-cultured) control LNCs] (Figure 4B); (ii) a decreased
number of effector memory (antigen-specific) CD4
+ CD44
high/
CD62L
2 and CD44
high/CD27
2 T cells [22,23] (Figure 4C–F);
and, (iii) an increase of CD4
+ (antigen-specific) T cells releasing the
anti-inflammatory cytokines IL-4 and IL-10 (Figure 4G–L).
Quite distinct from what is described for immune regulatory
somatic mesenchymal stem cells (MSCs), our findings with NPCs
were not paralleled by an increase of T cell apoptosis [24,25] and/
or generation of CD4
+/Foxp3
+/CD25
+ regulatory T cells [26,27]
(data not shown). Finally, LNCs from co-cultures with NPCs (LNCs/
NPCs) were capable of adoptively transferring a significant milder
R-EAE compared to control LNCs, as indicated by clinical
(Figure 4M) and neuropathological findings (number of CNS
inflammatory infiltrates per mm
2: adoptive EAE transfer control
LNCs, 11.161.5; adoptive LNCs/NPCs, 2.660.6; p#0.0001; %
of demyelination/mm
2 of spinal cord: adoptive control LNCs,
5.660.0; adoptive LNCs/NPCs, 0.8760.2; p#0.0001; % of
axonal loss/mm
2 of spinal cord: adoptive control LNCs,
5.660.7; adoptive LNCs/NPCs, 0.6360.2; p#0.0001).
Restrainance of dendritic cell maturation trough soluble
bone morphogenetic proteins
The in vivo and in vitro finding that the expansion of antigen-
specific effector T cells is hampered in lymph nodes from s.c.-
injected R-EAE mice prompted us to speculate a causal
impairment of the antigen presentation capacities of professional
antigen presenting cells (APC), such as DCs.
Indeed, a significant down-regulation of the co-stimulatory
molecules CD80/B7.1 and CD86/B7.2 (Figure 5A and B), but not
MHC class-II, (data not shown) was found ex-vivo on DCs from
NPC-treated R-EAE mice, as compared to DCs from sham-
treated controls. This latter finding was further confirmed in vitro,
as DCs maturating upon exposure to either tumor necrosis factor
(TNF)-a or toll-like receptor (TLR) agonists [e.g., poly-IC,
lipoteichoic acid (LTA) and bacterial lipopolysaccharide (LPS)]
failed to up-regulate CD80/B7.1, CD86/B7.2 and MHC class-II
(Figure 5C–E and Figure S4), while producing significantly lowers
amounts of pro-inflammatory cytokines, when co-cultured with
NPCs (Figure 5F–G and Figure S4). This effect was observed
when DCs and NPCs were co-cultured both in the same dish as
well as in a trans well co-culture system avoiding cell-to-cell
contact (Figure 5C–G and Figures S4 and S5).
Interestingly enough, this impairment of the DC maturation
was reversible and it could be fixed if the NPCs were removed
from the co-culture in vitro system and DCs were put back on
maturation with fresh LPS (Figure 6).
Therefore, it would be very likely that, at least part of the
observed interference with DC maturation may be attributed to
NPCs releasing soluble immune-like molecules.
Recent evidence has shown that major developmental factors
controlling stem cell fate decisions during vertebrate embryo-
NPCs Restrain DC Function
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proteins, and the BMPs-2 and -4–also play a role in regulating
cell fate and determination in self-renewing tissues in adults,
such as the immune system and the haematopoietic system. In
one case, the involvement of the Hh signalling has been shown
in the negative regulation of the T cell differentiation in the
mouse thymus, both in the adult and the foetus [28,29]. But the
other hand, both Shh and BMP-2/-4 have been shown to
regulate the development and proliferation of haematopoietic
stem cells and the differentiation of mouse thymocytes
[29,30,31].
Therefore, the finding that lymph node DCs from R-EAE mice
are one of the preferential targets of the major environmental
regulators being increased at the level of ectopic germinal niche-like
lymph node areas, it is not completely surprising.
As such, DCs are found to express the whole apparatus (e.g.,
agonists, antagonists, receptors) for being both inducers as well as
targets of both BMPs and Shh. Both machineries were also
modulated at the mRNA level upon DC activation with LPS
(Figure 7A and B).
Indeed, BMP-4, but not Shh, was capable of down modulating
the membrane expression of CD80/B7.1, CD86/B7.2, and MHC
class II molecule, when added in vitro to DCs with LPS
(Figure 7C). Furthermore, the addition of the BMP antagonist
Noggin to both not treated as well as DCs maturating with LPS
did not exert any effect (Figure S6).
Figure 2. Electron microscopic in vivo appearance of s.c.-injected NPCs in draining lymph nodes. A, Transmission electron microscopy
(TEM) images a large-size immunogold-labelled GFP
+ NPC within a cervical lymph node of a R-EAE mouse at 72 days after cell injection. These GFP
+
cells display morphological and ultrastructural features similar to individual NPCs from neurospheres in vitro (see also Figure S3). The NPC
(pseudocolor green) takes contact with four individual lymph node cells (pseudocolor orange). The NPC shows an irregular and invaginated nucleus
(n) with a single nucleolus (nu), and its cytoplasm contains abundant organelles; B, Individual GFP
+ NPCs establishing anatomical contacts with two
GFP
2 lymph node cells–one of which (upper right) possesses the morphological characteristics of lymph blasts–through polarized microvilli (boxed
area). Note the electrodense grain precipitates within the cytoplasm (arrows) and on the membrane (arrowheads and boxed area); C–E, NPCs in
lymph nodes establish cell-to-cell contacts with lymph blasts through cytoplasmic expansions (C) or elongated intercellular junctions (D).
Transplanted NPCs are occasionally found in deeper contact and enclosing resident lymph cells (E). Images refer to representative draining lymph
nodes from R-EAE mice injected s.c. with NPCs at 3 and 10 dpi. Scale bars in A and B: 2 mm, in C and E: 1 mm, and in D: 500 nm.
doi:10.1371/journal.pone.0005959.g002
Figure 3. Establishment of atypical perivascular lymph node niches. A–D, Representative confocal microscope images of the persistence of
s.c.-injected NPCs (arrowheads, green) within lymph node perivascular areas in R-EAE mice at 75 dpi. Focal expression of tenascin C (A, red), BMP-4 (B,
red), BMP-7 (C, red) and Shh (D, red) are shown. Dashed lines represent blood vessels. Nuclei in A–D are counterstained with DAPI. Scale bars: A,
50 mm; C and D, 100 mm. E–G, Western blot analysis of BMP-4 (E), Noggin (F) and Shh (G) expression in cervical and axillary lymph nodes from sham-
treated (white dots) and NPC-injected (black dots) R-EAE mice at 2 weeks after treatment. Results from individual mice (n=3/group) are represented
as dots and expressed as protein Arbitrary Units (AU, fold induction over average naive) (6SEM). Data refer to R-EAE mice injected s.c. with NPCs at 3
and 10 dpi and sacrificed at two weeks after cell injection. *p#0.05; **p#0.005, vs. sham-treated controls.
doi:10.1371/journal.pone.0005959.g003
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of the mitogen-activated protein kinases (MAPK) p38 and Erk1/2,
but not the classical Smad-dependent (data not shown) [32],
intracellular signalling pathways and, again, it was blocked by
the addition of Noggin (Figure 7D). As additional confirmation of
the central role played by BMP-4 in DC function only, we found
that Noggin (i) significantly reverted the inhibitory effect of BMP-4
on LPS-induced maturation of DCs (Figure 7C); and, (ii) restored
both the expression of co-stimulatory molecules and the capacity
to release pro-inflammatory cytokines of DCs co-cultured with
NPCs (Figure S4). Moreover, neither BMP-4 nor Shh interfered
with the proliferation of CD4
+ T lymphocytes stimulated with
CD3/CD28 in the absence of APCs (Figure 7E). As further
functional proof, Noggin reverted the antigen presentation
capacity of naive PLP-pulsed DCs co-cultured with NPCs in vitro
(Figure 7F).
Then, in order to conclusively demonstrate whether the
observed immune regulatory effect was indeed specific for NPCs,
we challenged the capacity of other somatic stem cells, such as
bone marrow derived MSCs and vessel-associated mesoangioblasts
(MSAs), of interfering with the expression of co-stimulatory
molecules, when co-cultured with DCs maturating in vitro with
LPS. Interestingly enough, neither MSCs nor MSAs showed
significant inhibitory capacity of the expression of CD80/B7.1
(Figure 8A), CD86/B7.2 (Figure 8B), and MHC-II (Figure 8C) on
DCs, as compared to NPCs. More importantly, the addition of the
BMP antagonist Noggin was capable to restore the high levels of
co-stimulatory molecule expression when DCs were co-cultured
with NPCs and the BMP-secreting [33] ATDC5 condrogenic
precursor cells only (Figure 8A–C).
Discussion
Somatic stem cell-based therapies–including those delivering
NPCs–are broadly advised as potential alternative medicines
aiming at, in this case brain repair for invalidating CNS diseases.
This directive has arisen from the demonstration that NPC-driven
clinico-pathological recovery is achieved in several pre-clinical
Figure 4. NPCs inhibit generation of effector T cells. A, Ex vivo proliferation of lymph node cells (LNCs) from sham- (black bars) and NPC-
treated (white bars) R-EAE mice. Mice (n=15 mice/group) were treated with either the carrier solution or NPC s.c. at 3 dpi and sacrificed at 10 dpi; B,
Response to PLP139–151 of LNCs co-cultured with NPCs (LNCs/NPCs) either in the same well (white bars) or in a trans-well system (grey bars). Note
the significant suppression of proliferation, compared to control LNCs (black bars). No significant interference with T cell response is observed in
trans-well experiments. Data in A and B are mean Proliferation Index (over basal proliferation) (6SEM) from a total of n$3 independent experiments.
*p#0.05; **p#0.005, vs. control LNCs; C–F, LNCs/NPCs (D and F) show reduced percentages of CD44
high/CD62L
2 and CD44
high/CD27
2 CD4
+ effector
memory T cells, compared to control LNCs (C and E); G–L, LNCs/NPCs show reduced percentages of IFN-c- (y axis) and IL-2-producing (x axis in L)
CD4
+ T cells, while higher percentages IL-4- (x axis in J), IL-10-producing (x axis in K) CD4
+ T cells, compared to control LNCs (G, H and I, respectively);
M, Adoptive transfer to naive SJL recipients of PLP139–151-specific LNCs having being either co-cultured (LNCs/NPCs, white circles, n=8 mice) or not
(LNCs, black circles, n=13 mice) with NPCs. Note the significant impairment of EAE development (e.g., delay of the disease onset and reduction of the
clinical score), when disease is adoptively transferred with LNCs/NPCs. Data are mean clinical score (6SEM). *p#0.05; **p#0.005.
doi:10.1371/journal.pone.0005959.g004
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5959models of neurological disorders [7]. While the replacement of
lost/damaged cells was until few years ago assumed as the prime
therapeutic mechanism of CNS stem cells [3,13], it has now
become clear that transplanted somatic stem cells may simulta-
neously instruct several therapeutic mechanisms amongst which
cell replacement, itself, does not prevail. To understand and
elucidate the overall therapeutic potential of stem cells in
neurological diseases, namely the capacity of stem cells to adapt
their fate and function(s) to specific different pathological
conditions, we and others have recently proposed the concept of
therapeutic plasticity [7].
The transplantation of different sources of somatic stem cells
(e.g. NPCs [3,4,6,13], haematopoietic stem cells (HSCs) [34,35],
mesenchymal stem cells (MSCs) [36,37]), with very little (if any)
capability of neural (trans) differentiation, has promoted diffuse
CNS repair via intrinsic neuroprotective bystander capacities. This
neuroprotective capability, mainly exerted by undifferentiated
stem cells releasing in situ, a milieu of neuroprotective and
immunomodulatory molecules, is temporally and spatially orches-
trated by environmental needs. Moreover, more recent evidence,
including the study herein, has suggested that the majority of the
stem cell-mediated therapeutic effects in inflammatory CNS
disorders are possibly taking place peripherally, at the level of
immune relevant anatomical site, such as secondary lymphoid
organs [8,9,36]. Yet, a current and comprehensive illustration of
the different mechanism(s) by which such cells exert their
therapeutic potential is lacking.
Herein we report the capacity of NPCs to target, and synergize
with immune cells in draining lymph nodes, and have demon-
strated this by utilizing a highly peculiar protocol of therapeutic
passive (s.c.) NPC vaccination enhancing the capacity of injected
NPCs to selectively target the major peripheral sites of immune
surveillance (e.g., draining lymph nodes) in mice with EAE [38].
S.c.-injected NPCs protect mice from chronic CNS-confined
autoimmunity via an immune regulatory mechanism that restrains
the generation and expansion of pathogenic autoreactive T cells.
Regardless of the timing and the number of injections adminis-
tered, R-EAE mice injected with NPCs before the disease onset
showed significant clinical improvement, as compared to sham-
treated controls. By contrast, the delayed s.c. injection of NPCs did
not produce any detectable clinical improvement, as compared to
sham-treated controls. At this juncture, we do not have any clear-
cut mechanistic explanation in support of the lack of ‘treatment
effect’. However, based on broad evidence supporting the
potential of somatic stem cell-based therapies for the treatment
of neurological disorders [7,39], is the notion that NPCs exert a
broad regulatory capacity, that is dependent on the time of cell
injection, and that may be differentially exerted to specifically
interact with cells of different microenvironments in vivo
[6,8,9,36,37,40].
Further demonstrated is that the therapeutic potential is
sustained in vivo by the accumulation, survival and long-term
persistence exclusively at the level of secondary lymphoid organs of
the transplanted NPCs, which, in turn, modulate the in situ
increase of major stem cell fate determinants. In lymph nodes, the
increased bioavailability of BMP-4, BMP-7, Shh, and the BMP
antagonist Noggin, released by both transplanted NPCs and
immune cells, promotes the survival and persistence of s.c.-injected
NPCs outside the CNS, at the levels of ectopic perivascular germinal
niche-like lymph node areas.
Figure 6. The NPC-mediated restrainance of DC maturation is reversible upon the establishment of appropriate maturation
condition in vitro. The impairment of the expression of CD80/B7.1 (A), CD86/B7.2 (B) and MHC-II (C) by DCs maturating in vitro with LPS and being
co-cultured with NPCs (DCs/NPCs, grey bars) is restored if NPCs are removed from the upper chamber after 24 hours and new medium with LPS is
added for further 24 hours. White bars are not treated (NT) DCs, while black bars are control (non co-cultured) DCs. Data are mean RFI (6SEM) over
unstained DCs from a total of n=2 independent experiments. *p#0.05; **p#0.005, when either control DCs are compared to NT or DC/NPCs are
compared to control DCs.
doi:10.1371/journal.pone.0005959.g006
Figure 5. NPCs restrain DC maturation and cytokine production. A and B, Ex vivo FACS analysis of DCs from the lymph nodes of R-EAE mice
treated with either the carrier solution or NPC s.c. at 3 dpi and sacrificed at 7 dpi. The injection of NPCs hinders the up-regulation of CD80 (white
bars) and CD86 (black bars) on maturating DCs from cervical and axillary lymph nodes. Histograms in A and B are representative of the FACS analysis
for CD80 and CD86 on CD11c
+ lymph node DCs from cervical and axillary lymph nodes of naive (blue lines) and R-EAE mice either sham- (red lines) or
NPC-treated (green lines). The grey lines are the fluorescence minus one (FMO) control staining. Data are mean relative fluorescence intensity (RFI)
over FMO (6SEM) from a total of n=2 independent experiments (n=3 mice/group/experiment). up#0.05, vs. control DCs. *p#0.05 and **p#0.0005,
vs. sham-treated controls; C–E, Live NPCs (grey bars), but not PFA-fixed NPCs (fNPCs, green bars) and live NIH3T3 mouse embryonic fibroblasts
(orange bars), inhibit the up-regulation of CD80/B7.1 (C), CD86/B7.2 (D), and MHC-II (E) on DCs maturating in vitro with LPS. Cells were co-cultured
with DCs (1:1 NPC/DC ratio) in a trans-well system. White bars are not treated (NT) DCs, while black bars are control (non co-cultured) DCs. Data were
obtained from a total of n$3 independent experiments. Data in A–E are mean RFI over unstained (6SEM); F and G, Co-cultured NPCs significantly
inhibit the release of TNFa (F), while completely suppressing the release of IL-1a, IL-12p70 and IL-10 (G), from DCs maturating in vitro with LPS. NPCs
also favour the release of IL-15, IL-18 and M-CSF (G). Data are mean cytokine ng/ml (6SEM) from a total of n$3 independent experiments. C–G,
*p#0.05; **p#0.005, vs. control DCs.
doi:10.1371/journal.pone.0005959.g005
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PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e5959This latter is indeed a critical observation. It is in fact well
established that somatic stem cells injected systemically in
multifocal inflammatory CNS disorders, specifically accumulate
and persist for months at the level of inflamed perivascular CNS
areas, while promoting recovery [6,41,42,43,44,45]. In these
areas, named CNS atypical ectopic niches, a molecular cross talk
between the transplanted stem cells and CNS cells (e.g., reactive
astrocytes, inflamed endothelial cells and blood-borne infiltrating
T cells) takes place. The great majority of transplanted stem cells
survive within the CNS atypical ectopic niches, while displaying
undifferentiated features, owing to the focal release of develop-
mental stem cell regulators by immune cells and CNS resident
cells [6]. Also, surviving stem cells promote tissue protection by
releasing immunomodulatory and neurotrophic molecules [7].
Therefore, the establishment of atypical ectopic niches upon stem cell
therapy, at either the level of the CNS or in peripheral
immunologically relevant sites, might be realistically advised as
the functional (pre) requisite for the long-term therapeutic activity
of transplanted stem cells.
Furthermore, the observed excess of BMP-4 in lymph nodes
significantly impaired the maturation and antigen presentation
capacities of lymph node DCs, which, in turn, failed to sustain the
expansion and full activation of effector (encephalitogenic) T cells.
This effect was highly specific for BMP-4, as the BMP antagonist
Noggin significantly reverted the inhibitory effect of BMP-4 alone.
Interestingly enough, this BMP-4-dependent immune regulatory
effect on DCs was also highly specific for NPCs–but not for MSCs
or MSAs–as well as completely reversible after the removal of
NPCs from the co-cultures.
Our results–along with the recent demonstration that intrave-
nously-injected NPCs suppress T cell proliferation within second-
ary lymphoid organs [8] –provide additional mechanistic evidence
that CNS stem cells can be manipulated to act as immune
regulators in promoting CNS repair/protection. This is indeed the
first identification of a member of the transforming growth factor
(TGF)b/BMP family of stem cell developmental regulators as a
novel tolerogenic factor released by immune regulatory NPCs.
The phenomenon herein described may be indeed further
exploited as an efficient tool for vaccination therapy in
autoimmune inflammatory conditions, which result in widespread
CNS damage.
Importantly though, our observation follows some very recent
reports, which have started identifying some of the first
molecular mechanisms responsible for the somatic stem cell-
mediated regulatory effect on DCs. These have included the
demonstration that MSCs affect the DCs function trough the
release of (i) IL-6 inhibiting the differentiation to immature DCs
[46], (ii) Notch ligand Jagged-2, which induces the generation of
regulatory DCs [47] and, more recently, (iii) prostaglandin E2
inhibiting the differentiation to immature DCs [48]. Therefore,
while providing a much deeper molecular view of the
therapeutic plasticity of somatic stem cells, these findings and
our own data also predict a fairly transversal (inter-disease)
significance for most of the somatic stem cell-based approaches
aiming at immune regulation.
Critically important is for promoting CNS repair/protection the
ongoing study and the elucidation of the role(s) of CNS stem cells
in regenerative medicine and it will contribute to the development
of more efficacious (stem) cell-based therapies.
Materials and Methods
NPC derivation and cultures
Adult neurospheres were generated from the SVZ of four-to-
eight week-old SJL mice, as described [6]. Further information is
provided as Material S1.
EAE induction and NPC transplantation
Relapsing EAE was induced in a total of n=112 four-to-eight
week-old (weight 20–25 grams) female SJL mice, as described
[6]. At time of cell transplantation, single cell-dissociated NPCs
were injected sub-cutaneously in both flanks (0.5610
6 cell/
150 ml PBS in each site). Cell transplants with live NPCs were
performed prior to disease onset–at 3 and 10 dpi (n=35) or
10 dpi only (n=22) –or after the disease onset, at 30 dpi
(n=10). Paraformaldehyde (PFA)-fixed [5% PFA for 5 minutes
at room temperature (r.t.)] NPCs injected s.c. at 10 dpi (n=10)
were use as cellular controls. Sham-treated mice (n=35)
received 0.1 M PBS s.c. (150 ml in each site) at 3 and 10 dpi.
All procedures involving animals were performed according to
the guidelines of the Animal Ethical Committee of our Institute
(IACUC no. 265 to S.P.).Further information is provided as
Material S1.
In vitro expansion and adoptive transfer of PLP139–151-
specific mouse T cells
PLP139–151-specific T cells were obtained from the draining
lymph nodes of PLP139–151-immunized SJL mice, at 10 dpi, as
described [6]. Further information is provided as Material S1.
Figure 7. BMP-4-dependent hindrance of DC maturation. A and B, qRT-PCR analysis of BMPs/BMP antagonists, BMP receptors and Shh/Shh
receptors in DCs. Note the significant up-regulation of mRNA levels for Noggin (A) and ActvR 1 (B) and down-regulation of the Shh receptor
Smoothened (B) upon LPS activation of DCs. The mRNA levels of the other two BMP antagonists Chordin and Follistatin (A) remain unchanged after
LPS. Data are mean mRNA arbitrary units (FI over NPCs) (6SEM) from a total of n$3 independent experiments. *p#0.05; **p#0.005, vs. control DCs;
C, Soluble recombinant BMP-4, but not recombinant Shh, inhibits the up-regulation of CD80/B7.1, CD86/B7.2, and MHC-II on DCs maturating with
LPS. Almost complete reversion of the hindrance of DC maturation is obtained when soluble recombinant Noggin is added to the culture system. The
addition of the Shh antagonist Cyclopamine did not exert any effect. Data are mean RFI (6SEM) from a total of n$3 independent experiments.
*p#0.05, vs. control DCs; D, Immunoblot analysis of the TLR ligand-dependent activation of the MAPK p38 and Erk1/2 in DCs maturating with LPS in
vitro. Increased phosphorilation of Erk1/2–and to a lower extent of p38
MAPK–is obtained when BMP-4 (blue bars) is added to LPS-treated DCs (black
bars). The effect is reverted by the addition of the BMP-4 antagonist Noggin (red bars). White bars are not treated (NT) DCs. Values are ratios of
phosphorilated over total protein. Relative levels of protein expression were normalized to b actin; E, Proliferation to CD3/CD28 of lymph node CD4
+
T cells from naive SJL mice in presence of BMP-4 (grey bar) or Shh (orange bar). Neither of the two morphogens interferes with CD4
+ T cell response.
The white bar is the proliferation to CD3/CD28 only, while the black bar is the basal proliferation (no CD3/CD28). Data are mean proliferation index
(over basal proliferation) (6SEM) from a total of n=3 independent experiments; F, Proliferation of CD4
+ T cells from PLP139–151-immunized mice at
first re-call with the antigen in vitro that are co-cultured with naı ¨ve DCs which have been pulsed with PLP139–151 during the last 18 hours of LPS-
induced maturation (positive control, black circles). Significant reduction of antigen-specific proliferation of CD4
+ T cells is observed when DCs are co-
cultured with NPCs (white circles), while recovery of the antigen presenting efficiency is observed when the BMP-4 antagonist Noggin is added to the
DC/NPC co-culture (red circles). Grey circles are T cells co-cultured with non-activated DCs. Data are mean counts per minute (cpm) (6SEM) from a
total of n$3 independent experiments. *p#0.05, vs. positive control.
doi:10.1371/journal.pone.0005959.g007
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PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5959Figure 8. The BMP-4-dependent hindrance of DC maturation is specific for NPCs. A–C, NPCs (grey bars), but not bone marrow-derived
MSCs (blue bars), or vessel associated MSAs (green bars), inhibit the up-regulation of CD80/B7.1 (A), CD86/B7.2 (B), and MHC-II (C) on DCs maturating
in vitro with LPS. Almost complete recovery of the co-stimulatory molecule expression is obtained on DC/NPC only, when soluble recombinant
Noggin is added to the co-culture system. Cells were co-cultured with DCs (1:1 cell/DC ratio) in a trans-well system. White bars are not treated (NT)
DCs, while black bars are control (non co-cultured) DCs. BMP-secreting ATDC5 condrogenic cells (orange bars) are used as positive control. Data were
obtained from a total of n=2 independent experiments. Data in are mean RFI over unstained (6SEM). *p#0.05; **p#0.005, when either control DCs
are compared to NT, co-cultures are compared to control DCs or co-cultures plus Noggin are compared to co-cultures.
doi:10.1371/journal.pone.0005959.g008
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LNCs were isolated from inguinal, axillary, and paraorthic
lymph nodes of either naı ¨ve or PLP139–151-immunized mice at
10 dpi and suspended in RPMI complete medium. To examine
the effects of NPCs at the time of antigen presentation, LNCs
(7610
5/well) from PLP139–151-immunized mice were cultured in
triplicate in 200 ml in 96 well flat bottom microtiter plates (Costar),
stimulated with various concentrations of PLP139–151 (1–30 mg/
ml) and incubated at 37uC for 4 days. In co-cultures, single cell-
dissociated NPCs were added at 1:2 NPC/LNC ratio either to the
same well or to the upper chamber of a 0.4 mm membrane-
separated trans-well system (Nunc). Proliferation of LNCs was
determined by adding 1 mCi
3H-thymidine during the final
18 hours of the culture, as described. Data were expressed as
mean proliferation index (over basal proliferation) (6SEM) from a
total of n$4 independent experiments.
Dendritic cell (DC) preparation and co-cultures
Bone marrow-derived DCs were prepared from flushed tibias
and femurs of naive SJL mice (Charles River) and propagated in
vitro for 1 week in Iscove’s medium (Invitrogen Life Technol-
ogies) supplemented with 100 U/ml penicillin (BioWhittaker),
100 mg/ml streptomycin (BioWhittaker), 1.5 mM L-glutamine
(BioWhittaker), 10% heat-inactivated foetal calf serum (FCS;
EuroClone) and recombinant mouse GM-CSF and IL-4 (both
25 mg/ml, R&D System), as described [49]. In co-cultures, to
verify the effect of NPCs on DC maturation, single cell-
dissociated NPCs were added (1:1 NPC/DC ratio) at day 5,
either in the same well or in the upper chamber of a 0.4 mm
membrane-separated trans-well system (Nunc). Further informa-
tion is provided as Material S1. PFA-fixed mouse NPCs,
NIH3T3 embryonic fibroblasts [50], mouse mesoangioblasts
(MSAs) [51], bone marrow-derived mouse mesenchymal stem
cells (MSCs) [37] and the ATDC5 condrogenic cell line [52] (all
1:1 cell/DC ratio) were used as cellular controls. Further
information on MSA, MSC and ATDC5 cell preparations,
culture and phenotype is provided as Material S1.
Ex vivo characterization of DC cells from draining lymph
nodes
Mice were sacrificed at 7 days post immunization and axillary,
cervical and inguinal lymph nodes single-cell suspensions were
prepared by pressing the tissue through nylon cell strainer (70 mm,
BD Falcon). Cell suspensions were washed with complete media
and counted. To analyze CD11c
+ DC population the following
antibodies were used: CD11c (clone HL3), CD86 (clone GL1),
CD80 (clone 16-10A1), or MHC class II (clone M5/114.15.2). All
antibodies were conjugated to PE or APC and were purchased
from BD Biosciences/Pharmingen or Cedarlaine. For the analysis
of cell surface protein expression, 1,5610
6 lymph node cells were
stained with the antibodies above for 15 min at room temperature
in presence of 2 mg/ml of mouse IgG as FcR blocking reagent.
Cells were then washed in PBS and just before analysis on a
FACSCanto TM (Becton Dickinson). 7-Amino-actinomycin D (7-
AAD) was added for dead cell exclusion. A maximum of 5,000
events into the gate of CD11c cells were acquired for each sample.
Data were analyzed using FCS Express V3 (De Novo Software).
RT-PCR
Real-time quantitative PCR was performed using pre-developed
Taqman
TM Assay Reagents on an ABI Prism
TM 7700 Sequence
Detection System (Applied Biosystems) according to manufactur-
ers protocol. Further information is provided as Material S1.
Western blot analysis
Western blot analysis of BMP-4, Noggin and Shh was
performed using surgically dissected pairs of cervical and axillary
lymph nodes from naive SJL mice and both sham- and NPC-
treated R-EAE mice. Analysis of ERK1/2, phospho ERK1/2,
p38, phospho p38, SMAD 1 and phospho-SMAD1/5/8 proteins
expression was performed using not treated and LPS-treated DCs.
Further information is provided as Material S1.
Cytokine assay
Supernatants from DC/NPC co-colture experiments were
collected and cytokine production was analyzed with the Bioplex
Protein Array system (BioRad) using fluorescent beads specific for
mouse IL-1a, IL-2, IL-4, IL-10, IL-12 (p70), IFN-c, TNF-a, IL-
15, IL-18 and M-CSF, according to the manufacturer instructions
as described [53]. Samples were analysed in quadruplicate, and
fluorescence was read with the Luminex system (Biorad). Bio-plex
manager 4.0 software (Biorad) was used for the analysis of data.
FACS analysis
FACS analyses were carried out on a BD FACSCanto
TM
(Becton Dickinson), a FACSCalibur (Becton Dickinson) and a
CyAn
TM ADP (Dako), and data were analyzed using FlowJo
(Treestar) and CellQuest (BD Biosciences) software. At least
30.000 events were acquired for each sample. Complete list of
antibodies and further information are provided as Material S1.
Tissue pathology
At sacrifice mice were trans-cardially perfused with 4%
paraformaldehyde and CNS tissue (brain and spinal cord), liver,
spleen, kidneys and cervical, inguinal, axillary, mesenteric and
paraortic lymph nodes were removed and processed for pathology
on either paraffin-embedded or frozen tissue samples, as described
[6]. The complete list of antibodies used and further information is
provided as Material S1.
Immunogold and electron microscopy
At sacrifice, mice were perfused transcardially with 0.9% saline,
followed by 4% paraformaldehyde. The lymph nodes were
removed and post-fixed in the same fixative overnight. Further
information is provided as Material S1.
Histochemistry
Further information is provided as Material S1.
Statistical analysis
Data were compared using the Student’s t-test for paired or
unpaired data, the one-way Anova test or the Mann-Whitney U-
test for non-parametric data.
Supporting Information
Figure S1 A, EAE clinical score of PLP139-151-immunized SJL
mice, either sham-treated (black circles) or transplanted s.c. with
different NPC types. Only mice receiving passive vaccination with
live NPCs at both 3 and 10 dpi (white circles) and 10 dpi only
(grey circles) show pronounced clinical amelioration, when
compared to sham-treated controls. Delayed (namely 30 dpi, red
circles) s.c. live NPCs or paraformaldehyde-fixed s.c. NPCs at
10 dpi (blue circles) did not produce any detectable clinical
improvement. Data are mean clinical score (6SD) from a total of
n=2 independent experiments. B, Clinical features of R-EAE
mice injected s.c. with different NPC types. Data are mean
NPCs Restrain DC Function
PLoS ONE | www.plosone.org 13 June 2009 | Volume 4 | Issue 6 | e5959numbers (6SEM) from a total of n=2 independent experiments
*p,0.05; **p,0.005, vs. sham-treated controls.
Found at: doi:10.1371/journal.pone.0005959.s001 (2.65 MB TIF)
Figure S2 Phenotypical and morphological analysis of s.c.-
injected NPCs accumulating into draining lymph nodes of R-EAE
mice. A, Representative image of three s.c.-injected GFP+NPCs
(arrowheads) co-expressing doublecortin (DCX) within a cervical
lymph node. Scale bar: 40 mm. B, Representative image of two
distinct lymph node CD11b+professional phagocytes being
immune reactive also for GFP+. Scale bar: 10 mm. C, Transmis-
sion electron microscopy (TEM) of a vacuolized picnotic GFP+cell
in a representative axillary lymph node. Note the presence of
electron dense granules both in cytoplasm and cell surface. Scale
bar: 2 mm. Images in A–C refer to representative draining lymph
nodes from R-EAE mice injected s.c. with NPCs at 3 and 10 dpi
and sacrificed at 72 days after cell injection.
Found at: doi:10.1371/journal.pone.0005959.s002 (2.07 MB TIF)
Figure S3 TEM image of a NPC from a neurosphere in vitro.
Note the irregular nucleus, and the organelle-rich cytoplasm with
abundant mitochondria and endoplasmic reticulum. Morpholog-
ical and ultrastructural features of this single NPCs in vitro are
similar to the NPCs detected in vivo in lymph nodes (see also
Figure 2). Scale bar: 2 mm.
Found at: doi:10.1371/journal.pone.0005959.s003 (4.74 MB TIF)
Figure S4 The BMP antagonist Noggin reverts the hindrance of
DC maturation and cytokine production. A–C, Noggin (red bars)
almost completely reverts the down-regulation of CD80/B7.1 (A),
CD86/B7.2 (B), and MHC-II (C) obtained when DCs maturating
in vitro with different TLR agonists are co-cultured in trans-wells
with NPCs (white bars) (see also Figure 3). Black bars are non co-
cultured control DCs, while NT are not treated DCs. Data are
expressed as mean RFI over unstained (6SEM) from n.4
independent experiments. D, The addition of Noggin induces
substantial recovery of cytokine levels, whose production is
impaired in DC/NPC co-cultures. Data are mean cytokine levels
(ng/ml) (6SEM) from a total of n.3 independent experiments.
*p,0.05 and **p,0.005, vs. control DCs.
Found at: doi:10.1371/journal.pone.0005959.s004 (2.19 MB TIF)
Figure S5 NPCs inhibit the up-regulation of co-stimulatory
molecules upon LPS activation of DCs. Representative histograms
showing the fluorescence intensity for CD80/B7.1 (red lines),
CD86/B7.2 (green lines) and MHC-II (blue lines) on untreated
(NT) DCs, DCs activated with LPS and DCs activated with LPS
and co-cultured with NPCs in the same well. Black lines represent
isotype controls.
Found at: doi:10.1371/journal.pone.0005959.s005 (8.69 MB TIF)
Figure S6 The BMP antagonist Noggin alone does not interfere
with DC maturation in vitro. Soluble recombinant Noggin does
not interfere with the expression of CD80/B7.1 and CD86/B7.2
onto DCs undergoing maturation with LPS in vitro. Data are
mean RFI (6SEM) from a total of n=2 independent experiments.
**p,0.005, vs. control DCs.
Found at: doi:10.1371/journal.pone.0005959.s006 (1.45 MB TIF)
Figure S7 Phenotype of NPCs (A), bone marrow-derived MSCs
(B), vessel-associated MSAs (C) and ATDC5 condrogenic cells (D).
Histograms demonstrating the expression of surface molecules
(red) are overlaid with unstained controls (black).
Found at: doi:10.1371/journal.pone.0005959.s007 (2.77 MB TIF)
Material S1 Supplementary Materials and Methods
Found at: doi:10.1371/journal.pone.0005959.s008 (0.08 MB
DOC)
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